Optimizing The Daily Units Of Insulin; Insulin Degludec Aspart Versus Premixed Insulin Aspart In The Standard Of Care Regimen For Type 2 Diabetics
This study aimed to evaluate the impact of Insulin Degludec Aspart on daily insulin dose in comparison with premixed insulin aspart. It was a Quasi-Experimental study conducted in the Department of Pharmacology, Army Medical College, National University of Medical Sciences, Rawalpindi and the Depart...
Gespeichert in:
| Veröffentlicht in: | Journal of Ayub Medical College, Abbottabad Abbottabad, 2023-04, Vol.35 (2), p.294 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 2 |
| container_start_page | 294 |
| container_title | Journal of Ayub Medical College, Abbottabad |
| container_volume | 35 |
| creator | Malik, Komal Mumtaz Farhat, Kulsoom Ali, Shabana Noor, Mudassar Ahmad, Bilal |
| description | This study aimed to evaluate the impact of Insulin Degludec Aspart on daily insulin dose in comparison with premixed insulin aspart.
It was a Quasi-Experimental study conducted in the Department of Pharmacology, Army Medical College, National University of Medical Sciences, Rawalpindi and the Department of Medicine, Pak Emirates Military Hospital, Rawalpindi. One hundred and twenty participants with documented type 2 diabetes, taking premixed insulin aspart therapy were enrolled in the study. Sixty participants were substituted with insulin degludec aspart from premixed insulin aspart. Daily units of insulin were recorded for 12 weeks and compared for both groups. SPSS version 26 was used for analysing the study results.
Participants of the insulin degludec aspart group showed a significant reduction in the daily insulin dose compared to the premixed insulin aspart group. Fifty-two units per day were administered in the participants of the premixed insulin aspart patients while insulin degludec aspart participants received 40 units of median daily insulin dose (p-value |
| doi_str_mv | 10.55519/JAMC-02-11674 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_55519_JAMC_02_11674</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>37422824</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2054-dbf2d03b30ac72bab2a527001afe5d86e6bf6ce17ae3a4c3a440f54e5440e31b3</originalsourceid><addsrcrecordid>eNo9kMtOwzAURC0EoqWwZYn8Ayl-xHmIVZVSKCoqgpZtZMc3xShJIzuRKJ_BF5M-F1cz0p2ZxUHolpKhEILG9y-j18QjzKM0CP0z1KcRjT0W0ui884QJLxZR3ENXzn0TwhmPyCXq8dBnLGJ-H_3N68aU5tdUK7z4AjyWptjgZWUah-c5nlauLUz1cDR4DKui1ZDhkaulbfAnWNc6_GahND-gT7nDe1rtVj8aWWlp9XYykRbwO6xMCRWerC1ebGrADI-NVNCYzF2ji1wWDm4OOkDLyeMiefZm86dpMpp5GSPC97TKmSZccSKzkCmpmBQsJITKHISOAghUHmRAQwlc-ll3PsmFD6JT4FTxARrudzO7ds5CntbWlNJuUkrSHdx0CzclLN3B7Qp3-0LdqhL0KX6kyf8B_kl18g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Optimizing The Daily Units Of Insulin; Insulin Degludec Aspart Versus Premixed Insulin Aspart In The Standard Of Care Regimen For Type 2 Diabetics</title><source>MEDLINE</source><source>EZB Electronic Journals Library</source><creator>Malik, Komal Mumtaz ; Farhat, Kulsoom ; Ali, Shabana ; Noor, Mudassar ; Ahmad, Bilal</creator><creatorcontrib>Malik, Komal Mumtaz ; Farhat, Kulsoom ; Ali, Shabana ; Noor, Mudassar ; Ahmad, Bilal</creatorcontrib><description>This study aimed to evaluate the impact of Insulin Degludec Aspart on daily insulin dose in comparison with premixed insulin aspart.
It was a Quasi-Experimental study conducted in the Department of Pharmacology, Army Medical College, National University of Medical Sciences, Rawalpindi and the Department of Medicine, Pak Emirates Military Hospital, Rawalpindi. One hundred and twenty participants with documented type 2 diabetes, taking premixed insulin aspart therapy were enrolled in the study. Sixty participants were substituted with insulin degludec aspart from premixed insulin aspart. Daily units of insulin were recorded for 12 weeks and compared for both groups. SPSS version 26 was used for analysing the study results.
Participants of the insulin degludec aspart group showed a significant reduction in the daily insulin dose compared to the premixed insulin aspart group. Fifty-two units per day were administered in the participants of the premixed insulin aspart patients while insulin degludec aspart participants received 40 units of median daily insulin dose (p-value<0.001).
Insulin degludec aspart proved superior to premixed insulin aspart in a reduction in the daily dose of insulin with insulin degludec aspart.</description><identifier>ISSN: 1025-9589</identifier><identifier>EISSN: 1819-2718</identifier><identifier>DOI: 10.55519/JAMC-02-11674</identifier><identifier>PMID: 37422824</identifier><language>eng</language><publisher>Pakistan</publisher><subject>Blood Glucose ; Diabetes Mellitus, Type 2 - drug therapy ; Humans ; Hypoglycemic Agents - therapeutic use ; Insulin - therapeutic use ; Insulin Aspart - therapeutic use ; Standard of Care</subject><ispartof>Journal of Ayub Medical College, Abbottabad, 2023-04, Vol.35 (2), p.294</ispartof><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37422824$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Malik, Komal Mumtaz</creatorcontrib><creatorcontrib>Farhat, Kulsoom</creatorcontrib><creatorcontrib>Ali, Shabana</creatorcontrib><creatorcontrib>Noor, Mudassar</creatorcontrib><creatorcontrib>Ahmad, Bilal</creatorcontrib><title>Optimizing The Daily Units Of Insulin; Insulin Degludec Aspart Versus Premixed Insulin Aspart In The Standard Of Care Regimen For Type 2 Diabetics</title><title>Journal of Ayub Medical College, Abbottabad</title><addtitle>J Ayub Med Coll Abbottabad</addtitle><description>This study aimed to evaluate the impact of Insulin Degludec Aspart on daily insulin dose in comparison with premixed insulin aspart.
It was a Quasi-Experimental study conducted in the Department of Pharmacology, Army Medical College, National University of Medical Sciences, Rawalpindi and the Department of Medicine, Pak Emirates Military Hospital, Rawalpindi. One hundred and twenty participants with documented type 2 diabetes, taking premixed insulin aspart therapy were enrolled in the study. Sixty participants were substituted with insulin degludec aspart from premixed insulin aspart. Daily units of insulin were recorded for 12 weeks and compared for both groups. SPSS version 26 was used for analysing the study results.
Participants of the insulin degludec aspart group showed a significant reduction in the daily insulin dose compared to the premixed insulin aspart group. Fifty-two units per day were administered in the participants of the premixed insulin aspart patients while insulin degludec aspart participants received 40 units of median daily insulin dose (p-value<0.001).
Insulin degludec aspart proved superior to premixed insulin aspart in a reduction in the daily dose of insulin with insulin degludec aspart.</description><subject>Blood Glucose</subject><subject>Diabetes Mellitus, Type 2 - drug therapy</subject><subject>Humans</subject><subject>Hypoglycemic Agents - therapeutic use</subject><subject>Insulin - therapeutic use</subject><subject>Insulin Aspart - therapeutic use</subject><subject>Standard of Care</subject><issn>1025-9589</issn><issn>1819-2718</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kMtOwzAURC0EoqWwZYn8Ayl-xHmIVZVSKCoqgpZtZMc3xShJIzuRKJ_BF5M-F1cz0p2ZxUHolpKhEILG9y-j18QjzKM0CP0z1KcRjT0W0ui884QJLxZR3ENXzn0TwhmPyCXq8dBnLGJ-H_3N68aU5tdUK7z4AjyWptjgZWUah-c5nlauLUz1cDR4DKui1ZDhkaulbfAnWNc6_GahND-gT7nDe1rtVj8aWWlp9XYykRbwO6xMCRWerC1ebGrADI-NVNCYzF2ji1wWDm4OOkDLyeMiefZm86dpMpp5GSPC97TKmSZccSKzkCmpmBQsJITKHISOAghUHmRAQwlc-ll3PsmFD6JT4FTxARrudzO7ds5CntbWlNJuUkrSHdx0CzclLN3B7Qp3-0LdqhL0KX6kyf8B_kl18g</recordid><startdate>202304</startdate><enddate>202304</enddate><creator>Malik, Komal Mumtaz</creator><creator>Farhat, Kulsoom</creator><creator>Ali, Shabana</creator><creator>Noor, Mudassar</creator><creator>Ahmad, Bilal</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>202304</creationdate><title>Optimizing The Daily Units Of Insulin; Insulin Degludec Aspart Versus Premixed Insulin Aspart In The Standard Of Care Regimen For Type 2 Diabetics</title><author>Malik, Komal Mumtaz ; Farhat, Kulsoom ; Ali, Shabana ; Noor, Mudassar ; Ahmad, Bilal</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2054-dbf2d03b30ac72bab2a527001afe5d86e6bf6ce17ae3a4c3a440f54e5440e31b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Blood Glucose</topic><topic>Diabetes Mellitus, Type 2 - drug therapy</topic><topic>Humans</topic><topic>Hypoglycemic Agents - therapeutic use</topic><topic>Insulin - therapeutic use</topic><topic>Insulin Aspart - therapeutic use</topic><topic>Standard of Care</topic><toplevel>online_resources</toplevel><creatorcontrib>Malik, Komal Mumtaz</creatorcontrib><creatorcontrib>Farhat, Kulsoom</creatorcontrib><creatorcontrib>Ali, Shabana</creatorcontrib><creatorcontrib>Noor, Mudassar</creatorcontrib><creatorcontrib>Ahmad, Bilal</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Journal of Ayub Medical College, Abbottabad</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Malik, Komal Mumtaz</au><au>Farhat, Kulsoom</au><au>Ali, Shabana</au><au>Noor, Mudassar</au><au>Ahmad, Bilal</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Optimizing The Daily Units Of Insulin; Insulin Degludec Aspart Versus Premixed Insulin Aspart In The Standard Of Care Regimen For Type 2 Diabetics</atitle><jtitle>Journal of Ayub Medical College, Abbottabad</jtitle><addtitle>J Ayub Med Coll Abbottabad</addtitle><date>2023-04</date><risdate>2023</risdate><volume>35</volume><issue>2</issue><spage>294</spage><pages>294-</pages><issn>1025-9589</issn><eissn>1819-2718</eissn><abstract>This study aimed to evaluate the impact of Insulin Degludec Aspart on daily insulin dose in comparison with premixed insulin aspart.
It was a Quasi-Experimental study conducted in the Department of Pharmacology, Army Medical College, National University of Medical Sciences, Rawalpindi and the Department of Medicine, Pak Emirates Military Hospital, Rawalpindi. One hundred and twenty participants with documented type 2 diabetes, taking premixed insulin aspart therapy were enrolled in the study. Sixty participants were substituted with insulin degludec aspart from premixed insulin aspart. Daily units of insulin were recorded for 12 weeks and compared for both groups. SPSS version 26 was used for analysing the study results.
Participants of the insulin degludec aspart group showed a significant reduction in the daily insulin dose compared to the premixed insulin aspart group. Fifty-two units per day were administered in the participants of the premixed insulin aspart patients while insulin degludec aspart participants received 40 units of median daily insulin dose (p-value<0.001).
Insulin degludec aspart proved superior to premixed insulin aspart in a reduction in the daily dose of insulin with insulin degludec aspart.</abstract><cop>Pakistan</cop><pmid>37422824</pmid><doi>10.55519/JAMC-02-11674</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1025-9589 |
| ispartof | Journal of Ayub Medical College, Abbottabad, 2023-04, Vol.35 (2), p.294 |
| issn | 1025-9589 1819-2718 |
| language | eng |
| recordid | cdi_crossref_primary_10_55519_JAMC_02_11674 |
| source | MEDLINE; EZB Electronic Journals Library |
| subjects | Blood Glucose Diabetes Mellitus, Type 2 - drug therapy Humans Hypoglycemic Agents - therapeutic use Insulin - therapeutic use Insulin Aspart - therapeutic use Standard of Care |
| title | Optimizing The Daily Units Of Insulin; Insulin Degludec Aspart Versus Premixed Insulin Aspart In The Standard Of Care Regimen For Type 2 Diabetics |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-11T16%3A47%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Optimizing%20The%20Daily%20Units%20Of%20Insulin;%20Insulin%20Degludec%20Aspart%20Versus%20Premixed%20Insulin%20Aspart%20In%20The%20Standard%20Of%20Care%20Regimen%20For%20Type%202%20Diabetics&rft.jtitle=Journal%20of%20Ayub%20Medical%20College,%20Abbottabad&rft.au=Malik,%20Komal%20Mumtaz&rft.date=2023-04&rft.volume=35&rft.issue=2&rft.spage=294&rft.pages=294-&rft.issn=1025-9589&rft.eissn=1819-2718&rft_id=info:doi/10.55519/JAMC-02-11674&rft_dat=%3Cpubmed_cross%3E37422824%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/37422824&rfr_iscdi=true |